ProMeris

RSS

metaflumizone

Withdrawn
This medicine is now withdrawn from use in the European Union.

Overview

The marketing authorisation for ProMeris has been withdrawn at the request of the marketing authorisation holder.

This EPAR was last updated on 13/07/2015

Authorisation details

Product details
Name
ProMeris
Agency product number
EMEA/V/C/000107
Active substance
metaflumizone
International non-proprietary name (INN) or common name
metaflumizone
Species
Cats
Anatomical therapeutic chemical veterinary (ATCvet) codes
QP53AX25
Publication details
Marketing-authorisation holder
Pfizer Limited 
Revision
8
Date of issue of marketing authorisation valid throughout the European Union
19/12/2006
Contact address
Pfizer Limited
Ramsgate Road
Sandwich
Kent CT13 9NJ
United Kingdom

Product information

08/07/2015 ProMeris - EMEA/V/C/000107 - IB/0012

Product information documents contain:

  • summary of product characteristics (annex I);
  • manufacturing authorisation holder responsible for batch release (annex IIA);
  • conditions of the marketing authorisation (annex IIB);
  • labelling (annex IIIA);
  • package leaflet (annex IIIB).

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

Ectoparasiticides for topical use, incl. insecticides

Therapeutic indication

Treatment and prevention of flea infestations (Ctenocephalides canis and C. felis) in cats. The veterinary medicinal product can be used as part of a treatment strategy for flea allergy dermatitis (FAD).

Assessment history

How useful was this page?

Add your rating